retatrutide triple agonist weight loss trial Results:Trial Data and FDA Status Who Makes Retatrutide? Company Behind

For instance, in the pivotal SURPASS-2 trial, patients receiving the highest tirzepatide dose (15 mg) achieved a mean body weight reduction of 11.2 kg, nearly twice that observed with semaglutide 1 mg (5.7 kg) (19)

It is important to note that unlike prescription GLP-1 drugs, these patches are typically sold as supplements, and are not approved as GLP-1 medications by FDA for weight loss or diabetes management 3

While monocyte activity is generally impaired, transient increases during attacks have been observed

Meal replacement sales will decline sharply in 2025 as consumers trade calorie-restrictive meal systems for nutrient-packed offerings